Algenscribe is a pre-clinical stage biotechnology company developing a first-in-class Gene Replacement platform. The flexible platform aims to improve the efficiency and quality of Gene Editing from single bases to multi-kilobase replacements.

Algenscribe’s platform tackles technological challenges in gene editing:
1°) Boosts Efficiency: Dramatically increases gene replacement rates
2°) Enhances Precision: Minimizes nuclease-induced mutations
3°) Full-Scale Flexibility: Edits from single bases to multi-kilobase insertions
4°) Versatile Utility: Spans therapeutics and bioproduction
5°) Non-viral: Bypasses AAV-related delivery constraints.

HEPHAISTOS is a preclinical-stage biopharmaceutical company focused on designing and developing a third-generation innate immune activator. Its mission is to address a major challenge in oncology: improving patient responses to existing immunotherapies by overcoming myeloid-driven tumor immunosuppression.

The company’s lead candidate, HEPHA-440, enhances antitumor activity through multiple mechanisms. It promotes the recruitment of immune effector cells into the tumor microenvironment (TME), reverses macrophage polarization, activates dendritic cells and antigen presentation, and triggers CD8 T-cell–mediated cytotoxicity.

HEPHA-440 is an engineered small-molecule TLR4 agonist of the third generation. Compared to earlier clinical-stage compounds such as GLA and GSK1795091, it is 30 to 400 times safer, and it is twice as effective as first-generation molecules like GLA and MPL. It is also suitable for intravenous administration.

Preclinical studies have shown that HEPHA-440 achieves a balanced MyD88–TRIF signaling profile that favors antitumor cytokine production while maintaining low pyrogenicity. It has demonstrated strong single-agent efficacy, including complete tumor regressions and systemic effects against metastases. In combination therapies, it shows synergy with anti-PD-1 and anti-CD20 antibodies, achieving up to 100% complete tumor regression in some models. Additionally, it significantly increases PD-1 and PD-L1 expression within the tumor microenvironment.

HEPHAISTOS has been awarded funding from the EIC Accelerator ($3 million) and the France 2030 RHU program ($11.5 million), and has also received recognition from Sanofi and Amgen through their Golden Ticket programs.

Based in France, Curlim is an innovative biotech company focused on developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These debilitating conditions, such as Charcot–Marie–Tooth disease (CMT), affect tens of thousands of patients in Europe and the U.S. and currently have no curative treatments. CMT, the most common inherited peripheral neuropathy, affects approximately 1 in 5,000 individuals worldwide representing a major unmet medical need for patients worldwide.

Curlim has developed an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules for treating hereditary peripheral neuropathies and rare diseases. The benefits are better Solubility, better Stability, better Bioavailability and a significant increase of intra-cellular penetration (Trojan horse) allowing molecules to reach full therapeutic potential.

Curlim obtained unprecedented and spectacular therapeutic effects with significant rescue in the nerve function (demonstrated on 2 CMT1A animal models with no signs of toxicity, even with repeated doses. Some highlights : very significant improvement in Motor Nerve Conduction Velocities (MNCV) in all models and a normalisation of motor skills, with balance time on the bar not statistically different from normal rats.

Moreover, the platform is a flexible solution applicable to multiple drug candidates and therapeutic indications, far beyond neuropathies.

This makes Curlim not just a drug developer, but the owner of a scalable, high-value platform technology with long-term partnering and licensing potential.

Brenus Pharma is a French clinical-stage biotechnology company developing a new class of in vivo immunotherapies for solid tumors.

The company has built a proprietary, data-driven platform based on its Stimulated-Ghost-Cell (SGC) technology. It transforms tumor complexity into scalable, off-the-shelf therapeutic candidates by integrating multi-omics data, predictive validation models, and GMP-ready manufacturing. This approach enables cost control and broad patient access, overcoming key limitations of personalized therapies such as mRNA and CAR-T.

SGC technology reproduces tumor protein expression and makes these targets visible to the immune system. It captures tumor heterogeneity, including resistance and plasticity, and enables broad, multi-specific immune responses against evolving tumors.

The lead candidate, STC-1010, targets metastatic colorectal cancer, the second leading cause of cancer-related death worldwide. It is currently evaluated in a Phase I/II trial (NCT06934538) in advanced MSS CRC. Early data show a favorable safety profile and initial signs of immune engagement.

Upcoming milestones include U.S. IND submission, clinical data readouts, and a Series B financing.

THX Pharma (ALTHX) is a listed biopharmaceutical company dedicated to discovering and developing treatments for rare neurological disorders. THX Pharma has two lead assets, TX01 and Batten-1:

TX01 is a proprietary, high-concentration oral solution built on an approved active ingredient, specifically formulated to address specific unmet needs in two rare lysosomal storage disorders: Niemann-Pick disease type C and Gaucher disease. THX Pharma (ALTHX) is currently finalizing its marketing authorization dossier for submission to both the EMA and FDA before year-end, with regional launches to follow across additional territories by 2027, and a projected revenue milestone of ~€50M by 2032. To accelerate patient access globally, the company has established two strategic licensing partnerships: Exeltis (Insud Pharma Group) holds exclusive commercialization rights across Europe, Latin America, and the MENA region, while Biocodex covers the United States and Canada. THX retains APAC rights and is actively seeking out-licensing partners to complete its global coverage.

Batten-1 is a proprietary, high-concentration oral liquid formulation of miglustat, optimized to meet the specific needs of pediatric and dysphagic patients with Batten disease — a devastating rare neurological disorder. Early clinical evidence is compelling: Phase I/II data demonstrated clear target engagement, reductions in neuronal death markers, and stabilization signals, while real-world data have shown clinically meaningful visual acuity stabilization. Both the FDA and EMA have endorsed a single pivotal Phase 3 pathway, streamlining the path to approval across major markets. THX Pharma (ALTHX) is currently advancing its Phase 3 program alongside an optimized Early Access strategy, underpinned by orphan designation and patent protection extending to ~2047 — providing a durable competitive moat. The global development and commercialization rights have been exclusively licensed to Biocodex, ensuring a well-resourced partner to drive the program through to launch and beyond. Peak revenue is modeled at ~€200M by 2033 across target markets.

Beyond its clinical-stage assets, THX Pharma can leverage a proprietary discovery platform to identify and develop next-generation drug candidates based on antisense oligonucleotide (ASO) technology. Two programs are currently underway:

The first targets TFEB, a transcription factor widely regarded as the master regulator of autophagy — the cellular recycling process by which cells clear damaged proteins and organelles. Dysregulation of autophagy is implicated in a broad spectrum of degenerative conditions, including Parkinson’s disease, Alzheimer’s disease, ALS, and Huntington’s disease, positioning TFEB modulation as a high-value therapeutic axis across neurology and beyond.

The second program is focused on characterizing an undisclosed target with promising therapeutic potential in glioblastoma — the most aggressive and lethal primary brain tumor in adults, with a median survival of under 15 months and fewer than 5% of patients alive at five years; approximately 300,000 new cases are diagnosed worldwide each year. Both programs are conducted in collaboration with leading French academic teams specializing in ASO therapeutics, and the TFEB project has received formal recognition through a France 2030 grant awarded by Bpifrance — validating both the scientific rationale and the quality of the research partnership.

NFL Biosciences is a Phase 3 French publicly listed biotech company (ticker: ALNFL), developing NFL-101 and NFL-102, disruptive drug candidates for smoking cessation with a new and distinctive mechanism of action.

NFL-101 has recently completed a randomized, double-blind, placebo-controlled, three-arm Phase 2b trial (two doses and placebo; n=318 patients) with a 12-month follow-up. The treatment involves two subcutaneous injections administered one week apart, optimizing both compliance and efficacy. NFL Biosciences has been able to show superiority of NFL-101 vs placebo, with an efficacy similar to Champix, the gold standard in smoking cessation therapy. Unlike Champix, NFL-101 shows no serious side effects and has a convenient dosing schedule.

NFL-102 is now entering a Phase 2b study.

To continue the development of NFL-101 beyond the Phase 2b CESTO-II clinical trial, and also NFL-102, the company would be keen to enter into discussions with potential new investors and pharmaceutical companies.

Igyxos is a French biotechnology company dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. Igyxos’ lead asset is IGX12, a first-in-class humanized monoclonal antibody which is Phase 2 ready.